,0,1
0,urea cycle disorder,9.0
1,listing rules,9.0
2,biomarker strategy,9.0
3,solid tumors,8.967741935483872
4,subsidiary corporations,8.88888888888889
5,expenditure limitation,8.762820512820513
6,credit quality,8.666666666666666
7,rated banks,8.615384615384615
8,shareholder approval,8.517857142857142
9,toxicology studies,8.514285714285714
10,disease therapy,8.5
11,global market,8.327868852459016
12,manufacturing partner,8.324242424242424
13,product candidate,8.24561403508772
14,product candidate,8.24561403508772
15,product candidate,8.24561403508772
16,fasb issued asu,8.214634146341464
17,months,8.212121212121211
18,toxicology studies,8.196103896103896
19,consolidated statements,8.173160173160174
20,committed capital,8.124125874125873
21,accounting policies,8.07173601147776
22,amino acid arginine,8.058823529411764
23,capital expenditure requirements,8.057692307692308
24,additional equity,8.056818181818182
25,examination,8.051282051282051
26,repurchase agreements,8.037037037037038
27,royalty consideration,8.026607538802661
28,investor relations,8.004566210045663
29,digit percentages,8.0
30,life science companies,8.0
31,genetic diseases,8.0
32,stock split,7.979661016949152
33,split certificate,7.976470588235294
34,contract manufacturing organization,7.957575757575757
35,accounting pronouncements,7.949186991869919
36,product candidate,7.927432216905901
37,regulatory approval,7.891190476190475
38,regulatory approval,7.891190476190475
39,regulatory approval,7.891190476190475
40,regulatory approval,7.891190476190475
41,human enzymes,7.846153846153847
42,resources functions,7.841524216524217
43,property portfolio,7.829326923076923
44,1/2 protocol,7.819444444444445
45,public offering,7.8180484225972116
46,capital resources,7.812678062678063
47,contract manufacturing organizations,7.809427609427608
48,direct incremental legal,7.785714285714286
49,tax benefits,7.746091307066917
50,additional funding,7.717532467532467
51,repeat dosing,7.714285714285714
52,money market funds,7.694535519125683
53,additional costs,7.686384391863844
54,additional personnel,7.681818181818182
55,financial statements,7.664388243335612
56,product candidate,7.662280701754385
57,balance sheet arrangements,7.659113300492611
58,monetary amount,7.648484848484848
59,grant contract,7.648087431693989
60,lease classifications,7.623068630973769
61,capital stock,7.621968709256845
62,trial,7.620915032679738
63,government regulation,7.588235294117647
64,substantial losses,7.567619047619048
65,circulating levels,7.551282051282051
66,preferred stock,7.549423330107692
67,regulatory approval,7.5340476190476195
68,acid metabolism,7.5019607843137255
69,digit multiple,7.5
70,trial sites,7.496142719382835
71,credit risk,7.491551459293396
72,financial statements,7.47391205285942
73,cancer treatments,7.473076923076923
74,biotechnology company,7.470149253731343
75,aeglea biotherapeutics holdings,7.462406015037594
76,office space,7.461956521739131
77,equity incentive plans,7.458333333333334
78,clinical trials,7.453103216191529
79,form cystine,7.45
80,additional funds,7.4387287509238735
81,common stock,7.426648968756382
82,accounting model,7.423704898206006
83,dollar terms,7.421052631578947
84,product candidates,7.418027828191168
85,product candidates,7.418027828191168
86,stock appreciation rights,7.410430247718383
87,grant revenues,7.3874813710879295
88,obligation,7.384615384615385
89,shelf registration statement,7.357142857142858
90,intellectual property,7.3556427125506065
91,additional financing,7.324675324675324
92,annual periods,7.31789594053745
93,clinical trials,7.3167395798278925
94,escalation trial,7.309803921568626
95,underwriting discounts,7.300000000000001
96,unrealized gains,7.3
97,development activities,7.298684210526315
98,patent rights,7.286324786324786
99,preferred stock,7.251616088904225
100,quarterly report,7.25
101,offering price,7.2391010541761585
102,stock units,7.235216572504708
103,tax positions,7.232371794871795
104,drug product,7.225412014885698
105,equity instruments,7.208333333333334
106,arginine levels,7.2081447963800915
107,interest income,7.2072170585019135
108,amino acids,7.205882352941177
109,arginine excess,7.20024174053183
110,manufacturing expenses,7.187165356573251
111,grant,7.178267611874169
112,outstanding grant,7.178267611874169
113,liquid investments,7.17094017094017
114,expansion arms,7.166666666666666
115,income tax expense,7.166572674637191
116,gross proceeds,7.153401797175867
117,tax assets,7.129941239316239
118,significant expenses,7.117559523809524
119,nonclinical expenses,7.10254557384026
120,product candidates,7.099846010009349
121,manufacturing expenses,7.089420995670995
122,loss position,7.088400488400488
123,contract research organizations,7.08054942359578
124,proceeds,7.072756635885543
125,market data,7.07072599531616
126,service period,7.055181023720349
127,sec regulations,7.053571428571429
128,additional capital,7.052697302697303
129,security deposit requirement,7.035294117647059
130,research companies,7.03498687992003
131,party service providers,7.017460317460317
132,nonclinical expenses,7.0048012129380055
133,compensation arrangements,6.997227997227997
134,approval milestones,6.991190476190477
135,valuation allowance,6.986194808775455
136,license agreements,6.984405458089669
137,product candidates,6.968027828191167
138,nonclinical studies,6.965019466906259
139,rent liability,6.963312368972747
140,contract manufacturing costs,6.962141967621419
141,service providers,6.961904761904762
142,vesting schedule,6.958333333333334
143,accounting policies,6.952688392430143
144,common stock,6.940162482269896
145,financial institutions,6.916136495083863
146,financial statements,6.906812485759854
147,employee headcount,6.902972027972028
148,performance date,6.9
149,clinical trials,6.882396145484458
150,reimbursable costs,6.879566210045662
151,working capital,6.878021978021978
152,efforts,6.874509803921569
153,increased costs,6.871232876712329
154,reporting period,6.871054039593366
155,research organizations,6.8668882214099884
156,development programs,6.865724762726488
157,contracted amounts,6.863829787234042
158,costs,6.862803757938383
159,topline data,6.85
160,common stock,6.841283115097845
161,contractual obligations,6.834175084175084
162,require,6.829905613512171
163,safety monitoring,6.826330532212885
164,party transactions,6.817460317460318
165,interim periods,6.813566936208446
166,owned subsidiaries,6.809523809523808
167,milestone payments,6.801282051282051
168,financial instruments,6.8007518796992485
169,adverse effect,6.8
170,preferred share,6.77626637819919
171,preferred shares,6.772988119610153
172,cash equivalents,6.766871363930187
173,amount,6.756818181818182
174,payment obligations,6.750841750841751
175,payment accounting,6.75046904315197
176,cash equivalents,6.743061840120664
177,stage biotechnology company,6.742876526458616
178,intellectual property,6.698892140468228
179,license fee,6.689792663476874
180,noncumulative dividends,6.684210526315789
181,period presentation,6.664842859469141
182,hematological malignancies,6.662812133400369
183,patent application,6.65
184,clinical trials,6.647997363140471
185,development capabilities,6.643502540504266
186,current liabilities,6.640182030625423
187,accumulated depreciation,6.625152625152625
188,accounts,6.617135050741608
189,common stock,6.6158381579455705
190,adverse impact,6.6083333333333325
191,stock awards,6.607943845231981
192,net loss,6.601788165568734
193,equity securities,6.595946285140562
194,aeglea biotherapeutics,6.595739348370927
195,executive officer,6.571428571428571
196,product revenues,6.561819568684557
197,lease agreement,6.557434225490939
198,cash rent payments,6.553846153846154
199,nonclinical studies,6.549272594205744
200,expenses,6.53096198156682
201,income tax impact,6.527936311000827
202,operating expenses,6.526098220186951
203,market prices,6.507763032353196
204,prepaid expenses,6.499765037593985
205,development activities,6.498684210526316
206,capital resources sources,6.47934472934473
207,transfers,6.470149253731343
208,fair values,6.458662660920105
209,administrative expenses,6.456214985994398
210,prior period,6.44947676077518
211,lease agreements,6.4432028834480315
212,expenses,6.430779789084584
213,development expenses,6.429001237850724
214,schedule,6.4275362318840585
215,common stock,6.426648968756382
216,substantial losses,6.424761904761905
217,rent payments,6.416666666666667
218,revenue,6.412606572683719
219,operating activities,6.404792339535096
220,funding requirements,6.404185320851987
221,shares,6.403225806451613
222,operating history,6.3911717495987155
223,revenue share,6.386896221903395
224,revenue share,6.386896221903395
225,related costs,6.368079159084927
226,modification,6.365853658536585
227,clinical proof,6.365126676602086
228,research activities,6.364662484024631
229,lease agreement,6.360294286777966
230,revenue,6.347058823529412
231,activities cash,6.342192018507808
232,insurance premiums,6.341589267285862
233,stock options,6.313355687229189
234,company obligation,6.309310092892183
235,basis,6.290275761973875
236,leasehold improvements,6.28888888888889
237,tiered royalties,6.282795698924731
238,additional shares,6.274233177458984
239,stock options,6.2573780782727715
240,payment awards,6.257342657342658
241,grant revenues,6.254148037754595
242,operating plan,6.2468653313792535
243,pipeline product candidates,6.241557239955873
244,development costs,6.196960305039244
245,net loss,6.1900234596863815
246,related expenses,6.1751200918964075
247,common shares,6.1637272717723555
248,development expenses,6.149326441102756
249,issuance price,6.146052631578947
250,accrued expenses,6.1404532967032965
251,market sales agreement,6.120706970245344
252,administrative expenses,6.118960084033613
253,comprehensive loss,6.113553113553113
254,research laboratory,6.10589055420007
255,contract research,6.105409900511052
256,lease classification,6.099719194580855
257,office lease agreement,6.098936201775524
258,blood arginine levels,6.097033685268979
259,grant revenue,6.095146255223401
260,based awards,6.094741031326397
261,accounting fees,6.080139372822299
262,therapeutics,6.070707070707071
263,operating losses,6.058790797217764
264,lesser amount,6.042424242424243
265,lease term,6.003305785123968
266,clinical trials,5.978832204184668
267,research,5.978024012846686
268,service period,5.930181023720349
269,stated maturities,5.9185185185185185
270,annual increase,5.9120670995671
271,class method,5.897832817337461
272,restated certificate,5.870220588235294
273,qualified expenditures,5.868671679197995
274,cash proceeds,5.844781826360773
275,results support,5.837221633085896
276,ten years,5.825396825396825
277,market participants,5.819507648445638
278,marketable securities,5.813958333333333
279,guidance,5.8
280,administrative expenses,5.797881652661064
281,stage company,5.782876526458615
282,future payments,5.767792302106027
283,research,5.745983080035206
284,operating results revenue,5.731145787994562
285,event advance payments,5.720760233918129
286,reimbursement,5.692223678462211
287,development costs,5.671671473203557
288,benefits,5.671368765926465
289,lived assets,5.668402777777779
290,related notes,5.661904761904762
291,office space,5.631599378881988
292,net losses,5.620453380642618
293,payment award,5.551282051282052
294,approvals,5.540856324438414
295,identical terms,5.539933750460067
296,current liabilities,5.533039173482566
297,costs,5.526467421602046
298,amended lease,5.518267906336089
299,grant revenue,5.461812921890068
300,marketable securities,5.432562984496124
301,worldwide license,5.419590643274854
302,fair values,5.393445269615757
303,agreement,5.385955709459335
304,convertible preferred,5.36976231315854
305,current operations,5.339622641509434
306,profitable operations,5.284067085953879
307,manufacturing organizations,5.276094276094276
308,digit royalty,5.2727272727272725
309,sale price,5.224624060150376
310,amino acids,5.205882352941177
311,llc conversion,5.177045177045177
312,cost basis,5.163724893487522
313,management estimates,5.14201994223918
314,digit,5.136363636363637
315,apply asu 2014,5.133333333333333
316,liability company,5.131874321116788
317,highly uncertain,5.052884615384615
318,owned subsidiaries,5.031746031746032
319,administrative functions,4.977941176470589
320,split certificate,4.976470588235294
321,regulatory approval,4.891190476190476
322,external providers,4.8730158730158735
323,primarily consist,4.857142857142858
324,nonclinical studies,4.853908355795149
325,human diseases,4.846153846153847
326,working capital,4.842307692307692
327,schedule,4.833333333333334
328,research,4.8321801588086055
329,public offering,4.8180484225972116
330,related party,4.817460317460318
331,licensed product,4.8011695906432745
332,financial instruments,4.8007518796992485
333,unrealized gains,4.800000000000001
334,tax bases,4.794871794871795
335,management,4.778280542986425
336,clinical trials,4.7712850343733475
337,gross proceeds,4.7631578947368425
338,milestone payments,4.75
339,financial position,4.745196324143693
340,clinical manufacturing,4.743914555389965
341,preferred stock,4.738102575390711
342,manufacturing capabilities,4.702020202020202
343,additional personnel,4.681818181818182
344,manufacturing activities,4.676874003189793
345,valuation allowance,4.668734491315137
346,applied prospectively,4.666666666666666
347,grant,4.664754098360655
348,financial statements,4.664388243335612
349,balance sheet,4.659113300492611
350,balance sheet,4.659113300492611
351,balance sheet,4.659113300492611
352,proceeds,4.653401797175866
353,expenses,4.650400246305418
354,contract,4.648087431693989
355,interim periods,4.64690026954178
356,credit risk,4.634408602150538
357,trial,4.620915032679738
358,applicable product,4.620614035087719
359,expense,4.613636363636363
360,financial institutions,4.608444187391555
361,hematological malignancies,4.603988603988604
362,operating activities,4.600946185688942
363,ongoing trial,4.5931372549019605
364,administrative expenses,4.589548319327731
365,expenses,4.584921749598716
366,internal regulatory,4.583859649122807
367,recent developments,4.583333333333334
368,recent developments,4.583333333333334
369,public certificate,4.58072590738423
370,laboratory space,4.575
371,clinical response,4.5696721311475414
372,current economic,4.565217391304348
373,market participants,4.558638083228248
374,additional paid,4.556818181818182
375,drug administration,4.555555555555555
376,related expenses,4.5540674603174605
377,enzyme,4.55
378,development programs,4.546052631578947
379,activities,4.538345864661654
380,interim period,4.537720706260032
381,outstanding liability,4.532381438041815
382,higher personnel,4.526315789473684
383,product revenues,4.5183413078149925
384,service providers,4.517460317460317
385,studies,4.514285714285714
386,remain outstanding,4.513513513513514
387,nonclinical candidates,4.512036434612883
388,accounts,4.502380952380952
389,patent,4.5
390,front fee,4.5
391,performance milestones,4.5
392,systemic depletion,4.5
393,expenses,4.499765037593985
394,immediately prior,4.496277915632755
395,clinical trial,4.496142719382835
396,tax purposes,4.494871794871795
397,amount,4.481818181818182
398,funds,4.481420765027322
399,data,4.476712328767123
400,manufacturing development,4.470295055821372
401,aeglea biotherapeutics,4.462406015037594
402,aeglea biotherapeutics,4.462406015037594
403,aeglea biotherapeutics,4.462406015037594
404,aeglea biotherapeutics,4.462406015037594
405,aeglea biotherapeutics,4.462406015037594
406,office space,4.461956521739131
407,current assets,4.455842391304348
408,contingent,4.454545454545455
409,annual report,4.450757575757576
410,common stock,4.426648968756382
411,deferred revenue,4.42483660130719
412,cancer therapy,4.423076923076923
413,redemption values,4.421052631578947
414,costs,4.418359313493938
415,product candidates,4.418027828191168
416,internal laboratory,4.410526315789474
417,net proceeds,4.409225310467179
418,operating lease,4.406165846410994
419,grant revenues,4.387481371087929
420,based payment,4.384615384615385
421,expenses,4.382948606271777
422,period,4.380085238279737
423,contractual obligations,4.37962962962963
424,proceeds,4.377911993097498
425,additional research,4.3771824202287775
426,applicable sublicense,4.375
427,regulatory agencies,4.373333333333333
428,capital,4.370879120879121
429,payment,4.37037037037037
430,class method,4.368421052631579
431,funds,4.366666666666667
432,cash,4.359401709401709
433,administrative costs,4.35750738651625
434,registration statement,4.357142857142858
435,nonclinical testing,4.339622641509434
436,average black,4.333333333333334
437,market acceptance,4.327868852459016
438,advantageous market,4.327868852459016
439,development capabilities,4.3238304093567255
440,valuation methodology,4.32258064516129
441,ongoing basis,4.322327044025157
442,related costs,4.3220265275059795
443,penalties,4.317460317460318
444,technology,4.317460317460318
445,revenues,4.316205533596838
446,accrual balance,4.314285714285715
447,exercise price,4.309941520467836
448,academic institutions,4.3076923076923075
449,accumulated depreciation,4.3076923076923075
450,financial condition,4.3007518796992485
451,financial breaches,4.3007518796992485
452,financial institution,4.3007518796992485
453,financial instrument,4.3007518796992485
454,underwriting discounts,4.3
455,period,4.299625468164794
456,development activities,4.298684210526316
457,twelve months,4.295454545454545
458,sec requirements,4.293956043956044
459,substantial portion,4.285714285714286
460,development expenses,4.28265977443609
461,fixed number,4.277777777777778
462,restated certificate,4.276470588235294
463,performance awards,4.2727272727272725
464,regulatory approvals,4.262222222222222
465,income taxes,4.258064516129032
466,financing activities,4.252631578947368
467,quarterly report,4.25
468,qualified expenditures,4.247619047619048
469,common stockholder,4.246987951807229
470,increased headcount,4.241666666666667
471,basis,4.238993710691824
472,operating assets,4.238939606741573
473,allowable expenses,4.236607142857142
474,security,4.235294117647059
475,security deposit,4.235294117647059
476,similar securities,4.233217592592593
477,based therapeutics,4.233100233100233
478,subscription rights,4.230769230769231
479,product revenue,4.226006191950464
480,annual amount,4.224242424242425
481,lived assets,4.223958333333334
482,related notes,4.217460317460318
483,internal personnel,4.210526315789474
484,interest income,4.2072170585019135
485,losses,4.201647940074906
486,laboratory supplies,4.2
487,laboratory facilities,4.2
488,laboratory spaces,4.2
489,values,4.196052631578947
490,advance payments,4.194444444444445
491,financial assets,4.1913768796992485
492,net loss,4.1900234596863815
493,early application,4.1899999999999995
494,accumulated deficit,4.1826923076923075
495,separate indications,4.181818181818182
496,prices,4.17989417989418
497,stock bonuses,4.179661016949153
498,incentives,4.170731707317073
499,reimbursement,4.166666666666666
500,temporary equity,4.1644736842105265
501,identical assets,4.163352272727273
502,development expense,4.159688995215311
503,purchase period,4.155481324020649
504,funding,4.150468384074941
505,similar assets,4.1498842592592595
506,sufficient resources,4.148148148148148
507,differences,4.146341463414634
508,development milestones,4.146052631578947
509,obtain fda,4.142857142857142
510,stock options,4.142623979912115
511,stock options,4.142623979912115
512,periods,4.134295227524972
513,material deviations,4.133333333333333
514,contract amendment,4.133333333333333
515,related disclosures,4.126984126984127
516,stock compensation,4.125606962895098
517,outstanding number,4.124624624624625
518,total stock,4.120837487537388
519,rental expense,4.113636363636363
520,expense,4.113636363636363
521,cumulative expense,4.113636363636363
522,expenses,4.106172360248447
523,000 payment,4.102564102564102
524,revenue,4.095146255223401
525,lease agreements,4.094888276706459
526,future nonclinical,4.0927090612625205
527,related carrying,4.092460317460318
528,arginine metabolism,4.090196078431372
529,service provider,4.088888888888889
530,service condition,4.088888888888889
531,office facilities,4.086956521739131
532,product sales,4.084323712507074
533,lease liability,4.076719164197724
534,subsequent periods,4.0754716981132075
535,liability,4.070149975810353
536,agreement,4.068882538727628
537,presented prospectively,4.0588235294117645
538,stock,4.056373345716276
539,patent protection,4.055555555555555
540,service period,4.055181023720349
541,typically based,4.051282051282051
542,valuations,4.051282051282051
543,valued based,4.051282051282051
544,funds,4.0508771929824565
545,development costs,4.05061884162461
546,restated license,4.0473684210526315
547,successful development,4.046052631578947
548,development projects,4.046052631578947
549,proof,4.045454545454545
550,assets,4.044471153846153
551,loss,4.043956043956044
552,aggregate proceeds,4.040935672514619
553,cash expenses,4.040453296703297
554,expenditures,4.02903981264637
555,debt facility,4.027777777777778
556,comprehensive income,4.019969278033795
557,clinical research,4.015036369558137
558,marketable securities,4.013958333333333
559,lease agreement,4.011979680036394
560,costs,4.004566210045662
561,costs,4.004566210045662
562,actual costs,4.004566210045662
563,inborn errors,4.0
564,private placements,4.0
565,fluctuate significantly,4.0
566,myelodysplastic syndrome,4.0
567,discontinuation rates,4.0
568,compliance,4.0
569,technical merits,4.0
570,ultimate settlement,4.0
571,readily apparent,4.0
572,historical experience,4.0
573,publicly traded,4.0
574,table,4.0
575,legal fees,4.0
576,materially incorporate,4.0
577,dual approach,4.0
578,retroactively adjusted,4.0
579,necessarily indicative,4.0
580,proprietary technology,4.0
581,sponsored agencies,4.0
582,united states,4.0
583,bond issuers,4.0
584,orderly transaction,4.0
585,active markets,4.0
586,dilution provisions,4.0
587,sole source,4.0
588,tables,4.0
589,primarily attributable,4.0
590,temporarily impaired,4.0
591,tables sets,4.0
592,european commission,4.0
593,hyperargininemia secondary,4.0
594,corporate matters,4.0
595,tables,4.0
596,interim cmo,4.0
597,units,4.0
598,american college,4.0
599,medical genetics,4.0
600,emerging standards,4.0
601,cutaneous melanoma,4.0
602,uveal melanoma,4.0
603,net losses,3.9994007490636703
604,based compensation,3.997227997227997
605,future annual,3.9955106621773284
606,licensed products,3.9930555555555554
607,disclosures,3.991341991341991
608,license,3.9908466819221973
609,net sales,3.9847770931496918
610,license agreements,3.984405458089669
611,largest amount,3.981818181818182
612,development efforts,3.9793859649122805
613,protocol amendment,3.975
614,individual securities,3.973958333333333
615,participating securities,3.973958333333333
616,securities,3.973958333333333
617,incremental fair,3.9723926380368098
618,risk,3.967741935483871
619,inherent risk,3.967741935483871
620,period,3.966292134831461
621,development expenditures,3.9603383458646615
622,sublicense agreement,3.9541284403669725
623,employment agreement,3.9541284403669725
624,payables,3.9523809523809526
625,compensation costs,3.9505121559916083
626,cash,3.950187617260788
627,awards,3.9496503496503497
628,interest,3.9491525423728815
629,ownership interest,3.9491525423728815
630,quarterly basis,3.9473270440251573
631,remaining term,3.9454545454545453
632,lesser number,3.9444444444444446
633,average number,3.9444444444444446
634,contractual maturities,3.935185185185185
635,based awards,3.924009324009324
636,cancer prevention,3.9230769230769234
637,conversion feature,3.9230769230769234
638,cancer cells,3.9230769230769234
639,manufacturing services,3.9193880553103853
640,earnings history,3.9172413793103447
641,aeglea llc,3.9147869674185465
642,cash equivalents,3.9097285067873306
643,line basis,3.9056603773584904
644,current operations,3.9048400328137816
645,license agreement,3.901496861419604
646,accompanying notes,3.9
647,thereto,3.9
648,losses,3.896811594202899
649,research laboratory,3.895364238410596
650,fair values,3.893445269615757
651,disposed assets,3.890625
652,partial exercise,3.888888888888889
653,liability method,3.887288977159881
654,services,3.8853895335069852
655,company,3.8847834000728065
656,company,3.8847834000728065
657,toxic levels,3.8846153846153846
658,costs,3.8795662100456623
659,reclassifying,3.8767123287671232
660,allowances,3.8767123287671232
661,homocystine,3.8767123287671232
662,public company,3.8744045728802794
663,management,3.874125874125874
664,increased costs,3.871232876712329
665,pipeline development,3.8695820433436534
666,identification method,3.8684210526315788
667,line method,3.8684210526315788
668,allocation method,3.8684210526315788
669,debt financings,3.861111111111111
670,company,3.8603931561703675
671,remaining shares,3.8577712609970676
672,expenses,3.8576597744360903
673,products,3.8541666666666665
674,securities,3.8506706621004563
675,devoted substantially,3.8461538461538463
676,cash flows,3.840883190883191
677,profitable operations,3.839622641509434
678,amounts,3.8388297872340424
679,commercial sales,3.838709677419355
680,risks,3.8374603174603177
681,debt securities,3.8350694444444446
682,benefits,3.831219512195122
683,interest,3.8291525423728814
684,future periods,3.8285581178662937
685,shares,3.8225806451612905
686,planned research,3.820364238410596
687,shares,3.8178599527930763
688,related goods,3.8174603174603177
689,research grant,3.810118336771252
690,invention disclosures,3.8095238095238093
691,comprehensive loss,3.8058608058608057
692,consulting costs,3.804566210045662
693,cash,3.8038461538461537
694,cash,3.8038461538461537
695,fair market,3.800261490495826
696,competing drugs,3.8
697,tumor types,3.8
698,impairment loss,3.793956043956044
699,sales agreement,3.792838117786327
700,employee compensation,3.7920997920997923
701,temporary differences,3.7894736842105265
702,estimated grant,3.781420765027322
703,risks,3.779259259259259
704,determined based,3.7785547785547786
705,holding company,3.7778415614236507
706,nature,3.7777777777777777
707,agency securities,3.7739583333333333
708,accrued liability,3.768867924528302
709,leases,3.766919257904364
710,fiscal years,3.761904761904762
711,existing awards,3.7616161616161614
712,continuing development,3.7603383458646613
713,amount,3.756818181818182
714,amounts,3.756137479541735
715,amounts,3.756137479541735
716,consulting agreement,3.754128440366973
717,foreseeable future,3.753086419753086
718,future prospects,3.753086419753086
719,future success,3.753086419753086
720,funded activities,3.7526315789473683
721,life impairment,3.75
722,payments,3.75
723,payments,3.75
724,awards,3.747727272727273
725,eligible compensation,3.7459459459459463
726,llc conversion,3.7326007326007327
727,lease,3.7245179063360885
728,accounts payable,3.7216117216117217
729,company,3.720149253731343
730,aggregate total,3.718954248366013
731,agreements,3.718855218855219
732,recorded based,3.717948717948718
733,historically represented,3.7142857142857144
734,twelve years,3.7142857142857144
735,common stockholders,3.713654618473895
736,potential impact,3.7130952380952382
737,sublicenseable licenses,3.7
738,research institute,3.695364238410596
739,continued research,3.695364238410596
740,research grants,3.695364238410596
741,sponsored research,3.695364238410596
742,actual research,3.695364238410596
743,research,3.695364238410596
744,advisory services,3.6951456310679616
745,existing cash,3.692735042735043
746,principal offices,3.6923076923076925
747,management bases,3.6923076923076925
748,management,3.6923076923076925
749,purchase date,3.689189189189189
750,employees,3.687645687645688
751,amounts,3.6848824188129896
752,automatic increase,3.669642857142857
753,effect,3.666666666666667
754,early adoption,3.665
755,lease amendment,3.6578512396694216
756,research agreement,3.6494926787775688
757,potential commercialization,3.6471861471861473
758,recorded revenue,3.647058823529412
759,differ materially,3.642857142857143
760,delaware llc,3.642857142857143
761,differ significantly,3.642857142857143
762,observable inputs,3.642857142857143
763,fiscal year,3.641821946169772
764,normal range,3.6363636363636367
765,contracted services,3.6284789644012942
766,future awards,3.6258136924803592
767,costs,3.6256188416246093
768,report,3.625
769,continuing basis,3.6199460916442048
770,sec,3.619747899159664
771,date,3.6147540983606556
772,travel expenses,3.611607142857143
773,adequate number,3.611111111111111
774,variable number,3.611111111111111
775,principal expenditures,3.6065934065934067
776,depend heavily,3.6
777,respective affiliates,3.6
778,calendar year,3.5942028985507246
779,relevant year,3.5942028985507246
780,purchase shares,3.592414995640802
781,outstanding series,3.5904365904365907
782,fees,3.5892857142857144
783,significant research,3.576316619362977
784,related uncertainties,3.5674603174603177
785,million contingent,3.567255286679747
786,month period,3.5662921348314605
787,year period,3.5604950333821854
788,cancer indications,3.5594405594405596
789,management,3.5589743589743588
790,identical asset,3.5557461406518014
791,part,3.552631578947368
792,integral part,3.552631578947368
793,lease term,3.5487603305785127
794,aemase exclusive,3.5483091787439616
795,prepaid asset,3.5461767626613705
796,low single,3.545454545454546
797,marketing exclusivity,3.5454545454545454
798,1 prices,3.5428571428571427
799,temporary impairment,3.5394736842105265
800,redemption event,3.526315789473684
801,risks,3.52
802,original maturities,3.5185185185185186
803,short maturities,3.5185185185185186
804,undistributed earnings,3.5172413793103448
805,consulting fees,3.5142857142857142
806,employee member,3.5128205128205128
807,gains,3.5076923076923077
808,salaries,3.5034843205574915
809,adoption,3.5017123287671232
810,personnel,3.5
811,item,3.5
812,primarily due,3.5
813,exchange commission,3.5
814,ultimately expected,3.5
815,dividend,3.5
816,maturity,3.5
817,professional services,3.4951456310679614
818,capitalized amounts,3.4804964539007095
819,measuring fair,3.4723926380368098
820,measure fair,3.4723926380368098
821,tier,3.4723926380368098
822,fair statement,3.4723926380368098
823,share amounts,3.4703338522746927
824,company,3.470149253731343
825,company,3.470149253731343
826,company,3.470149253731343
827,company adjusts,3.470149253731343
828,company,3.470149253731343
829,company,3.470149253731343
830,company,3.470149253731343
831,company measures,3.470149253731343
832,company,3.470149253731343
833,company,3.470149253731343
834,accounting standard,3.468417761100688
835,market conditions,3.4674037361799463
836,metabolic dependence,3.4545454545454546
837,duration,3.4523809523809526
838,accrued research,3.445364238410596
839,successful discovery,3.4444444444444446
840,work,3.4375
841,eligible employees,3.4363636363636365
842,fully offset,3.4186046511627906
843,facilities leases,3.4186046511627906
844,eventual commercialization,3.409090909090909
845,largest component,3.409090909090909
846,share attributable,3.40650406504065
847,issuable shares,3.403225806451613
848,shares,3.403225806451613
849,shares,3.403225806451613
850,risk factors,3.4025245441795233
851,actual results,3.402439024390244
852,results,3.402439024390244
853,stock option,3.401883239171375
854,lowest level,3.4
855,settled contractually,3.4
856,terminated earlier,3.4
857,declared effective,3.395833333333333
858,delaware corporation,3.395833333333333
859,revenue share,3.3868962219033953
860,materially affect,3.3846153846153846
861,hierarchy,3.384615384615384
862,patents,3.380952380952381
863,cash,3.3752747252747253
864,commercial sale,3.375
865,uncured default,3.375
866,time consuming,3.3666666666666667
867,penalties,3.3666666666666667
868,considered observable,3.365079365079365
869,university,3.3649064645986266
870,concurrently develop,3.357142857142857
871,primarily consisted,3.357142857142857
872,effective agreement,3.349961773700306
873,sale securities,3.348958333333333
874,company,3.345149253731343
875,company,3.345149253731343
876,company,3.345149253731343
877,company,3.345149253731343
878,operations,3.339622641509434
879,disclosures,3.3389355742296916
880,potential treatment,3.3380952380952382
881,company,3.33681592039801
882,operational plan,3.333333333333333
883,pricing models,3.333333333333333
884,unobservable inputs,3.333333333333333
885,day,3.333333333333333
886,subsequent amendments,3.333333333333333
887,time period,3.332958801498127
888,company,3.3272921108742004
889,aemase terminates,3.3260869565217392
890,cprit,3.3170731707317076
891,dilutive securities,3.3072916666666665
892,estimates,3.303370786516854
893,completion costs,3.2986838571044856
894,leases,3.2986046511627904
895,consulting services,3.295145631067961
896,sublicensees,3.2941176470588234
897,full term,3.290909090909091
898,significant component,3.29004329004329
899,equipment property,3.287202380952381
900,agreements,3.287037037037037
901,stockholders,3.2848484848484847
902,asset group,3.283018867924528
903,license,3.2734553775743707
904,automatically converted,3.27027027027027
905,company,3.2701492537313435
906,2 million driven,3.266555985980446
907,revenue recognition,3.2661064425770308
908,relevant assumptions,3.2608695652173916
909,million net,3.2587772478646295
910,approved products,3.2556818181818183
911,fund losses,3.253333333333333
912,employee share,3.252657911194497
913,aggregate fair,3.2501704158145874
914,numerous uncertainties,3.25
915,reimbursement result,3.247311827956989
916,service conditions,3.228423772609819
917,issuance thereunder,3.225
918,development,3.2246240601503757
919,forfeitures,3.2222222222222223
920,significant judgments,3.2142857142857144
921,securities,3.204727564102564
922,proportional reduction,3.2
923,company,3.1974219810040703
924,patients,3.186274509803922
925,adult patients,3.186274509803922
926,pediatric patients,3.186274509803922
927,subsequent events,3.1818181818181817
928,cancers,3.1764705882352944
929,fourth quarter,3.1724137931034484
930,sold pursuant,3.1719457013574663
931,increase significantly,3.169642857142857
932,subsequently extended,3.1538461538461537
933,estimated fair,3.1390593047034763
934,company,3.1368159203980097
935,company,3.1368159203980097
936,concentration limits,3.1333333333333333
937,shares,3.1304985337243405
938,analysis costs,3.1295662100456623
939,adoption date,3.125
940,royalties,3.112820512820513
941,6 million primarily,3.1127098321342928
942,3 million reclassified,3.1127098321342928
943,4 million primarily,3.1127098321342928
944,cancer patients,3.1093514328808447
945,year term,3.085111989459816
946,estimates,3.068076668869795
947,company,3.063899253731343
948,aecase license,3.0584795321637426
949,award,3.041666666666667
950,company,3.041577825159915
951,future collection,3.003086419753086
952,measurement date,3.0
953,recruiting services,2.9951456310679614
954,future issuance,2.9780864197530867
955,reasonable assurance,2.973684210526316
956,date,2.9723926380368098
957,company records,2.970149253731343
958,sublicensees,2.9607843137254903
959,restrictions,2.9444444444444446
960,services,2.9326456310679614
961,directors,2.923444976076555
962,record,2.916837082481254
963,determine fair,2.916837082481254
964,effective date,2.895833333333333
965,1 deficiency,2.893617021276596
966,potentially subject,2.887931034482759
967,0 million payable,2.881940601365062
968,information request,2.875
969,company shares,2.873375060182956
970,enrollment,2.869047619047619
971,investments,2.8412698412698414
972,operations,2.839622641509434
973,company,2.817088029241547
974,consolidated,2.8095238095238093
975,equipment,2.799557032115172
976,operations,2.784067085953878
977,million covering,2.7793764988009593
978,ipo,2.774774774774775
979,estimates,2.7533707865168537
980,liabilities,2.7472335468841003
981,company,2.7404195240016134
982,fund operations,2.739622641509434
983,7 million incurred,2.73376246371324
984,company,2.7333071484681852
985,policies,2.7058823529411766
986,additional 537,2.6818181818181817
987,current,2.5652173913043477
988,preferred,2.5584415584415585
989,million closing,2.541281260705721
990,effective january,2.533764367816092
991,contract,2.533333333333333
992,remaining,2.4545454545454546
993,deferred,2.4444444444444446
994,capital,2.4423076923076925
995,uncertain,2.4375
996,lower,2.4285714285714284
997,manufacturing,2.4242424242424243
998,price,2.4210526315789473
999,prior,2.4193548387096775
1000,issued,2.4146341463414633
1001,offering,2.413793103448276
1002,diluted,2.411764705882353
1003,received,2.3902439024390243
1004,obligation,2.3846153846153846
1005,equity,2.375
1006,resources,2.3703703703703702
1007,accounting,2.3658536585365852
1008,statements,2.3636363636363638
1009,single,2.3636363636363638
1010,operating,2.348314606741573
1011,nonclinical,2.339622641509434
1012,payment,2.3333333333333335
1013,dose,2.3333333333333335
1014,market,2.3278688524590163
1015,arginine,2.323529411764706
1016,clinical,2.319672131147541
1017,related,2.3174603174603177
1018,financial,2.300751879699248
1019,12 months,2.2954545454545454
1020,months,2.2954545454545454
1021,million increase,2.2823526892771495
1022,million increase,2.2823526892771495
1023,revenues,2.272727272727273
1024,stage,2.272727272727273
1025,proceeds,2.263157894736842
1026,similar,2.259259259259259
1027,income,2.2580645161290325
1028,payments,2.25
1029,142 common,2.246987951807229
1030,product,2.245614035087719
1031,annual,2.242424242424242
1032,potential,2.238095238095238
1033,expenses,2.236607142857143
1034,rights,2.230769230769231
1035,conducted,2.2
1036,purchase,2.189189189189189
1037,purchase 24,2.189189189189189
1038,require,2.1818181818181817
1039,stock,2.1796610169491526
1040,trial,2.176470588235294
1041,candidates,2.1724137931034484
1042,granted,2.1707317073170733
1043,beginning,2.1666666666666665
1044,application,2.15
1045,include,2.1463414634146343
1046,net,2.146067415730337
1047,observable,2.142857142857143
1048,subsidiaries,2.142857142857143
1049,presentation,2.1333333333333333
1050,material,2.1333333333333333
1051,contracted,2.1333333333333333
1052,grant,2.1147540983606556
1053,expense,2.1136363636363638
1054,conducting,2.111111111111111
1055,aeglea,2.1052631578947367
1056,service,2.088888888888889
1057,office,2.0869565217391304
1058,plans,2.0833333333333335
1059,periods,2.0754716981132075
1060,amounts,2.0638297872340425
1061,aml,2.0588235294117645
1062,lease,2.0578512396694215
1063,based,2.051282051282051
1064,development,2.0460526315789473
1065,loss,2.043956043956044
1066,generate,2.0434782608695654
1067,25%,2.0416666666666665
1068,early,2.04
1069,quoted,2.037037037037037
1070,agreements,2.037037037037037
1071,funding,2.0357142857142856
1072,liability,2.018867924528302
1073,costs,2.0045662100456623
1074,engineered,2.0
1075,initiate,2.0
1076,fully,2.0
1077,personnel,2.0
1078,positions,2.0
1079,relating,2.0
1080,financing,2.0
1081,statement,2.0
1082,specific,2.0
1083,carried,2.0
1084,deposit,2.0
1085,depreciation,2.0
1086,life,2.0
1087,amortized,2.0
1088,transactions,2.0
1089,reserved,2.0
1090,vesting,2.0
1091,% vesting,2.0
1092,transfers,2.0
1093,dividends,2.0
1094,basic,2.0
1095,officer,2.0
1096,review,2.0
1097,decreased,2.0
1098,provide,2.0
1099,diseases,2.0
1100,update,2.0
1101,amount,1.981818181818182
1102,revenue,1.9803921568627452
1103,securities,1.9739583333333333
1104,risk,1.967741935483871
1105,period,1.9662921348314606
1106,obligations,1.962962962962963
1107,505 options,1.962962962962963
1108,agreement,1.9541284403669725
1109,accounts,1.9523809523809523
1110,benefits,1.951219512195122
1111,interest,1.9491525423728813
1112,license,1.9473684210526316
1113,compensation,1.945945945945946
1114,advance,1.9444444444444444
1115,total,1.9411764705882353
1116,pursuant,1.9411764705882353
1117,efforts,1.9333333333333333
1118,raising,1.9285714285714286
1119,cancer,1.9230769230769231
1120,conversion,1.9230769230769231
1121,expenditures,1.9142857142857144
1122,property,1.90625
1123,basis,1.9056603773584906
1124,notes,1.9
1125,assets,1.890625
1126,blood,1.8888888888888888
1127,improvements,1.8888888888888888
1128,approvals,1.8888888888888888
1129,existing,1.8888888888888888
1130,levels,1.8846153846153846
1131,significant,1.880952380952381
1132,recognize,1.88
1133,including 481,1.8767123287671232
1134,including,1.8767123287671232
1135,paid,1.875
1136,deficit,1.875
1137,modified,1.875
1138,awards,1.8727272727272728
1139,resulting,1.8695652173913044
1140,method,1.868421052631579
1141,increased,1.8666666666666667
1142,believes,1.8666666666666667
1143,debt,1.8611111111111112
1144,generated,1.8571428571428572
1145,losses,1.8533333333333333
1146,employee,1.8461538461538463
1147,substantially,1.8461538461538463
1148,sales,1.8387096774193548
1149,delaware,1.8333333333333333
1150,unobservable,1.8333333333333333
1151,pipeline,1.8235294117647058
1152,approved,1.8181818181818181
1153,llc,1.8095238095238095
1154,disclosures,1.8095238095238095
1155,cash,1.8038461538461539
1156,guidance,1.8
1157,held,1.8
1158,consulting,1.8
1159,temporary,1.7894736842105263
1160,classification,1.7826086956521738
1161,aggregate,1.7777777777777777
1162,wholly,1.7777777777777777
1163,sufficient,1.7777777777777777
1164,carrying,1.775
1165,payable,1.7692307692307692
1166,metabolism,1.7666666666666666
1167,royalties,1.7666666666666666
1168,make,1.7647058823529411
1169,comprehensive,1.7619047619047619
1170,future,1.7530864197530864
1171,accrued,1.75
1172,impairment,1.75
1173,potentially,1.75
1174,determined,1.7272727272727273
1175,years,1.7142857142857142
1176,fees,1.7142857142857142
1177,represented,1.7142857142857142
1178,continuing,1.7142857142857142
1179,patents,1.7142857142857142
1180,dosing,1.7142857142857142
1181,purposes,1.7
1182,licenses,1.7
1183,research,1.695364238410596
1184,management,1.6923076923076923
1185,reported,1.6923076923076923
1186,principal,1.6923076923076923
1187,receive,1.6842105263157894
1188,receive $50,1.6842105263157894
1189,receive 57,1.6842105263157894
1190,signed,1.6818181818181819
1191,sec,1.6785714285714286
1192,closed,1.6666666666666667
1193,sources,1.6666666666666667
1194,estimated,1.6666666666666667
1195,effect,1.6666666666666667
1196,recorded,1.6666666666666667
1197,covering,1.6666666666666667
1198,modification,1.6666666666666667
1199,commenced,1.6666666666666667
1200,member,1.6666666666666667
1201,limited,1.6428571428571428
1202,differ,1.6428571428571428
1203,normal,1.6363636363636365
1204,indications,1.6363636363636365
1205,employees,1.6363636363636365
1206,21 employees,1.6363636363636365
1207,adoption,1.625
1208,incurred,1.6210526315789473
1209,gaap,1.6153846153846154
1210,number,1.6111111111111112
1211,amendment,1.6
1212,depend,1.6
1213,month,1.6
1214,affiliates,1.6
1215,year,1.5942028985507246
1216,amended,1.59375
1217,safety,1.588235294117647
1218,government,1.588235294117647
1219,enrollment,1.5833333333333333
1220,executive,1.5714285714285714
1221,includes,1.5714285714285714
1222,commercialize,1.5714285714285714
1223,provided,1.5714285714285714
1224,portion,1.5714285714285714
1225,corporation,1.5625
1226,protection,1.5555555555555556
1227,investments,1.5555555555555556
1228,part,1.5526315789473684
1229,demonstrated,1.5454545454545454
1230,exclusivity,1.5454545454545454
1231,required,1.5294117647058822
1232,event,1.5263157894736843
1233,risks,1.52
1234,maturities,1.5185185185185186
1235,earnings,1.5172413793103448
1236,pay,1.5161290322580645
1237,item,1.5
1238,survival,1.5
1239,date,1.5
1240,fda,1.5
1241,goods,1.5
1242,due,1.5
1243,reasonable,1.5
1244,recruiting,1.5
1245,funded,1.5
1246,exchange,1.5
1247,expected,1.5
1248,restrictions,1.5
1249,comparison,1.5
1250,made,1.5
1251,inputs,1.5
1252,records,1.5
1253,measurement,1.5
1254,dividend,1.5
1255,request,1.5
1256,maturity,1.5
1257,consisting,1.5
1258,services,1.4951456310679612
1259,term,1.490909090909091
1260,impact,1.475
1261,assurance,1.4736842105263157
1262,fair,1.4723926380368098
1263,requires,1.4705882352941178
1264,company,1.4701492537313432
1265,stockholders,1.4666666666666666
1266,dependence,1.4545454545454546
1267,form,1.45
1268,form 10,1.45
1269,arginase,1.446808510638298
1270,deficiency,1.446808510638298
1271,included,1.4444444444444444
1272,resulted,1.4444444444444444
1273,record,1.4444444444444444
1274,nature,1.4444444444444444
1275,discovery,1.4444444444444444
1276,determine,1.4444444444444444
1277,long,1.4444444444444444
1278,terminate,1.4444444444444444
1279,achieved,1.4444444444444444
1280,transfer,1.4444444444444444
1281,performed,1.4375
1282,products,1.4375
1283,factors,1.434782608695652
1284,support,1.434782608695652
1285,closing,1.4285714285714286
1286,cmo,1.4285714285714286
1287,terms,1.4210526315789473
1288,offset,1.4186046511627908
1289,leases,1.4186046511627908
1290,capitalized,1.4166666666666667
1291,entitled,1.4166666666666667
1292,insurance,1.411764705882353
1293,commercialization,1.4090909090909092
1294,component,1.4090909090909092
1295,share,1.4065040650406504
1296,940 shares,1.403225806451613
1297,shares,1.403225806451613
1298,496 shares,1.403225806451613
1299,000 shares,1.403225806451613
1300,948 shares,1.403225806451613
1301,233 shares,1.403225806451613
1302,184 shares,1.403225806451613
1303,results,1.4024390243902438
1304,18 results,1.4024390243902438
1305,level,1.4
1306,fund,1.4
1307,stated,1.4
1308,level,1.4
1309,settled,1.4
1310,08%,1.4
1311,level,1.4
1312,terminated,1.4
1313,effective,1.3958333333333333
1314,affect,1.3846153846153846
1315,equipment,1.380952380952381
1316,sale,1.375
1317,travel,1.375
1318,default,1.375
1319,information,1.375
1320,recognized,1.3666666666666667
1321,time,1.3666666666666667
1322,salaries,1.3571428571428572
1323,develop,1.3571428571428572
1324,consisted,1.3571428571428572
1325,entered,1.346938775510204
1326,reduce,1.3461538461538463
1327,operations,1.3396226415094339
1328,plan,1.3333333333333333
1329,judgments,1.3333333333333333
1330,collateral,1.3333333333333333
1331,6 concentration,1.3333333333333333
1332,concentration,1.3333333333333333
1333,pricing,1.3333333333333333
1334,hierarchy,1.3333333333333333
1335,amendments,1.3333333333333333
1336,2016 plan,1.3333333333333333
1337,2015 plan,1.3333333333333333
1338,day,1.3333333333333333
1339,starting,1.3333333333333333
1340,dilutive,1.3333333333333333
1341,inclusion,1.3333333333333333
1342,aemase,1.326086956521739
1343,cprit,1.3170731707317074
1344,realized,1.3076923076923077
1345,estimates,1.303370786516854
1346,completion,1.2941176470588236
1347,sublicensees,1.2941176470588236
1348,recognition,1.2857142857142858
1349,duration,1.2857142857142858
1350,sell,1.2857142857142858
1351,initiated,1.2857142857142858
1352,asset,1.2830188679245282
1353,converted,1.2702702702702702
1354,2016 filed,1.263157894736842
1355,filed,1.263157894736842
1356,assumptions,1.2608695652173914
1357,cost,1.2580645161290323
1358,uncertainties,1.25
1359,collection,1.25
1360,established,1.25
1361,worldwide,1.25
1362,director,1.25
1363,sold 5,1.2307692307692308
1364,sold,1.2307692307692308
1365,sold 18,1.2307692307692308
1366,issuance,1.225
1367,option,1.2222222222222223
1368,forfeitures,1.2222222222222223
1369,considered,1.2222222222222223
1370,liabilities,1.2178217821782178
1371,general,1.2083333333333333
1372,continue,1.2075471698113207
1373,initiation,1.2
1374,depending,1.2
1375,defined,1.2
1376,reduction,1.2
1377,retirement,1.2
1378,announced,1.2
1379,25%,1.2
1380,university,1.1941747572815533
1381,patients,1.1862745098039216
1382,low,1.1818181818181819
1383,events,1.1818181818181819
1384,expand,1.1785714285714286
1385,cancers,1.1764705882352942
1386,quarter,1.1724137931034482
1387,increase,1.1696428571428572
1388,000 increase,1.1696428571428572
1389,award,1.1666666666666667
1390,increases,1.1666666666666667
1391,primary,1.1666666666666667
1392,type,1.1666666666666667
1393,proceeding,1.1666666666666667
1394,decrease,1.1666666666666667
1395,extended,1.1538461538461537
1396,conditions,1.1395348837209303
1397,january 2016,1.1379310344827587
1398,subject,1.1379310344827587
1399,january 2015,1.1379310344827587
1400,january 1,1.1379310344827587
1401,january 2017,1.1379310344827587
1402,january 31,1.1379310344827587
1403,analysis,1.125
1404,completed,1.1176470588235294
1405,7 million,1.1127098321342925
1406,3 million,1.1127098321342925
1407,0 million,1.1127098321342925
1408,5 million,1.1127098321342925
1409,1 million,1.1127098321342925
1410,6 million,1.1127098321342925
1411,4 million,1.1127098321342925
1412,9 million,1.1127098321342925
1413,8 million,1.1127098321342925
1414,2 million,1.1127098321342925
1415,$150 million,1.1127098321342925
1416,anticipate,1.1111111111111112
1417,canada,1.1111111111111112
1418,occur,1.1111111111111112
1419,aecase,1.1111111111111112
1420,ipo,1.1081081081081081
1421,board,1.105263157894737
1422,directors,1.105263157894737
1423,standard,1.1025641025641026
1424,treatment,1.1
1425,result,1.0806451612903225
1426,series,1.0769230769230769
1427,anti,1.0769230769230769
1428,initiating,1.0714285714285714
1429,purchases,1.0588235294117647
1430,extent,1.05
1431,classified,1.0434782608695652
1432,august 31,1.0384615384615385
1433,august 2014,1.0384615384615385
1434,august 2016,1.0384615384615385
1435,discussion,1.0
1436,read,1.0
1437,conjunction,1.0
1438,rule 424,1.0
1439,refer,1.0
1440,prospectus,1.0
1441,parts,1.0
1442,forward,1.0
1443,objectives,1.0
1444,expectations,1.0
1445,intentions,1.0
1446,discussed,1.0
1447,contribute,1.0
1448,section,1.0
1449,overview,1.0
1450,field,1.0
1451,transform,1.0
1452,lives,1.0
1453,designed,1.0
1454,iem,1.0
1455,subset,1.0
1456,seeking,1.0
1457,oncology,1.0
1458,exploit,1.0
1459,degrade,1.0
1460,developed,1.0
1461,treat,1.0
1462,extremes,1.0
1463,shown,1.0
1464,ability,1.0
1465,dependent,1.0
1466,inception,1.0
1467,identifying,1.0
1468,financed,1.0
1469,april,1.0
1470,march 31,1.0
1471,raised,1.0
1472,april,1.0
1473,approximately $47,1.0
1474,commissions,1.0
1475,connection,1.0
1476,expect,1.0
1477,protect,1.0
1478,addition,1.0
1479,underwriters,1.0
1480,march,1.0
1481,food,1.0
1482,half,1.0
1483,intend,1.0
1484,mds,1.0
1485,assess,1.0
1486,tolerability,1.0
1487,pharmacokinetics,1.0
1488,enable,1.0
1489,components,1.0
1490,texas,1.0
1491,june,1.0
1492,june,1.0
1493,met,1.0
1494,submit,1.0
1495,end,1.0
1496,notably,1.0
1497,consultant,1.0
1498,parties,1.0
1499,expensed,1.0
1500,rendered,1.0
1501,delivered,1.0
1502,timing,1.0
1503,variety,1.0
1504,scope,1.0
1505,rate,1.0
1506,progress,1.0
1507,drop,1.0
1508,receipt,1.0
1509,process,1.0
1510,costly,1.0
1511,unable,1.0
1512,degree,1.0
1513,certainty,1.0
1514,succeed,1.0
1515,finance,1.0
1516,hiring,1.0
1517,consultants,1.0
1518,lawyers,1.0
1519,accountants,1.0
1520,additionally,1.0
1521,december,1.0
1522,march 10,1.0
1523,elected,1.0
1524,file,1.0
1525,partnership,1.0
1526,federal,1.0
1527,treated,1.0
1528,subchapter,1.0
1529,chapter,1.0
1530,serve,1.0
1531,noncurrent,1.0
1532,lack,1.0
1533,sustained,1.0
1534,policy,1.0
1535,relation,1.0
1536,prepared,1.0
1537,accordance,1.0
1538,preparation,1.0
1539,base,1.0
1540,circumstances,1.0
1541,evaluate,1.0
1542,compared,1.0
1543,determination,1.0
1544,estimating,1.0
1545,determining,1.0
1546,items,1.0
1547,dollars,1.0
1548,percentage,1.0
1549,* percentage,1.0
1550,multi,1.0
1551,austin,1.0
1552,preparing,1.0
1553,audit,1.0
1554,march 2015,1.0
1555,september,1.0
1556,liquidity,1.0
1557,collected $5,1.0
1558,reflected,1.0
1559,december,1.0
1560,commence,1.0
1561,advancement,1.0
1562,begin,1.0
1563,combination,1.0
1564,collaborations,1.0
1565,shareholders,1.0
1566,estimate,1.0
1567,prove,1.0
1568,incorrect,1.0
1569,thousands,1.0
1570,change,1.0
1571,november 2014,1.0
1572,december,1.0
1573,approximately $419,1.0
1574,2016 expires,1.0
1575,mid,1.0
1576,utilize,1.0
1577,percent,1.0
1578,repaid,1.0
1579,countries,1.0
1580,december,1.0
1581,respect,1.0
1582,achievement,1.0
1583,majority,1.0
1584,indication,1.0
1585,ranging,1.0
1586,breach,1.0
1587,cured,1.0
1588,60 days,1.0
1589,notice,1.0
1590,30 days,1.0
1591,challenge,1.0
1592,concern,1.0
1593,subtopic 205,1.0
1594,disclosure,1.0
1595,entity,1.0
1596,december,1.0
1597,february 2016,1.0
1598,topic,1.0
1599,establishes,1.0
1600,clarifies,1.0
1601,definition,1.0
1602,lessees,1.0
1603,permitted,1.0
1604,evaluating,1.0
1605,topic,1.0
1606,intended,1.0
1607,simplify,1.0
1608,areas,1.0
1609,item1,1.0
1610,unaudited,1.0
1611,formed,1.0
1612,december,1.0
1613,segment,1.0
1614,april,1.0
1615,ratio,1.0
1616,incorporation,1.0
1617,designated,1.0
1618,par,1.0
1619,june,1.0
1620,march 28,1.0
1621,filing,1.0
1622,order,1.0
1623,carry,1.0
1624,document,1.0
1625,reflect,1.0
1626,opinion,1.0
1627,adjustments,1.0
1628,derived,1.0
1629,summary,1.0
1630,conformity,1.0
1631,accruals,1.0
1632,delayed,1.0
1633,business,1.0
1634,therapies,1.0
1635,excluded,1.0
1636,declines,1.0
1637,judged,1.0
1638,experienced,1.0
1639,deposits,1.0
1640,monitored,1.0
1641,exposed,1.0
1642,printing,1.0
1643,computed,1.0
1644,straight,1.0
1645,repairs,1.0
1646,maintenance,1.0
1647,extend,1.0
1648,improve,1.0
1649,removed,1.0
1650,gain,1.0
1651,credited,1.0
1652,charged,1.0
1653,reviewed,1.0
1654,recoverable,1.0
1655,recoverability,1.0
1656,measured,1.0
1657,impairments,1.0
1658,cros,1.0
1659,cmos,1.0
1660,match,1.0
1661,materials,1.0
1662,proportion,1.0
1663,cro,1.0
1664,vary,1.0
1665,difference,1.0
1666,measurements,1.0
1667,establish,1.0
1668,framework,1.0
1669,selling,1.0
1670,transact,1.0
1671,nonperformance,1.0
1672,maximize,1.0
1673,minimize,1.0
1674,categorization,1.0
1675,input,1.0
1676,level2,1.0
1677,corroborated,1.0
1678,level3,1.0
1679,dates,1.0
1680,triggered,1.0
1681,deliver,1.0
1682,adjust,1.0
1683,note 1,1.0
1684,behalf,1.0
1685,dividing,1.0
1686,settle,1.0
1687,vest,1.0
1688,nonemployees,1.0
1689,remeasured,1.0
1690,continues,1.0
1691,distributions,1.0
1692,comprised,1.0
1693,reclassification,1.0
1694,reclassifications,1.0
1695,conform,1.0
1696,decline,1.0
1697,recovery,1.0
1698,changed,1.0
1699,comparing,1.0
1700,exceed $19,1.0
1701,exploiting,1.0
1702,execution,1.0
1703,reimbursed,1.0
1704,april,1.0
1705,effectiveness,1.0
1706,serves,1.0
1707,successor,1.0
1708,added,1.0
1709,2016 espp,1.0
1710,15%,1.0
1711,align,1.0
1712,acceleration,1.0
1713,asc 718,1.0
1714,weighted,1.0
1715,reports,1.0
1716,note 5,1.0
1717,holders,1.0
1718,participated,1.0
1719,distribution,1.0
1720,calculated,1.0
1721,distributed,1.0
1722,calculation,1.0
1723,preference,1.0
1724,allocated,1.0
1725,members,1.0
1726,perform,1.0
1727,exceed $386,1.0
1728,combined $1,1.0
1729,manufacture,1.0
1730,attainment,1.0
1731,country,1.0
1732,start,1.0
1733,phases,1.0
1734,region,1.0
1735,spouse,1.0
1736,founders,1.0
1737,founder,1.0
1738,hours,1.0
1739,commitments,1.0
1740,contingencies,1.0
1741,expires,1.0
1742,lessor,1.0
1743,retain,1.0
1744,reduced,1.0
1745,returned,1.0
1746,capacity,1.0
1747,16 item2,1.0
1748,october,1.0
1749,june,1.0
1750,intent,1.0
1751,pharmacodynamics,1.0
1752,july,1.0
1753,collected $6,1.0
1754,executing,1.0
1755,september 30,1.0
1756,september,1.0
1757,transferred,1.0
1758,amortization,1.0
1759,level1,1.0
1760,nditions,1.0
1761,set,1.0
1762,expiration,1.0
1763,collected $8,1.0
1764,deplete,1.0
1765,approximately $1,1.0
1766,reversal,1.0
1767,confirmed,1.0
1768,provision,1.0
1769,govern,1.0
1770,revised,1.0
1771,february 2017,1.0
1772,expire,1.0
1773,april,1.0
1774,salary,1.0
1775,warrants,1.0
1776,14 item2,1.0
1777,march,1.0
1778,target,1.0
1779,mechanism,1.0
1780,scenarios,1.0
1781,observed,1.0
1782,therapeutic,1.0
1783,submitted,1.0
1784,november,1.0
1785,broaden,1.0
1786,older,1.0
1787,march 2017,1.0
1788,follow,1.0
1789,middle,1.0
1790,tolerated,1.0
1791,care,1.0
1792,building,1.0
1793,metabolites,1.0
1794,cysteine,1.0
1795,methionine,1.0
1796,collected $10,1.0
1797,scaling,1.0
1798,amending,1.0
1799,investment,1.0
1800,june,1.0
1801,clarity,1.0
1802,reduces,1.0
1803,diversity,1.0
1804,practice,1.0
1805,complexity,1.0
1806,applying,1.0
1807,modifications,1.0
1808,consistent,1.0
1809,collected $12,1.0
